
Biotechnology Innovation
Manufacturing the Future of Medicine
Vivosel is a biotechnology company specializing in translational biotechnology, transforming advanced research into clinical-grade gene and cell therapies. With over 40 clinical trials and a GMP-licensed facility at Teknopark Istanbul, we pioneer the manufacturing of CAR-T cells, engineered exosomes, and mesenchymal stem cells for therapeutic use.
What Are MSCs?
Mesenchymal stem cells (MSCs) are specialized cells that can be obtained from bone marrow, adipose tissue, umbilical cord, and other tissues, with the potential to differentiate into various cell types.
Regenerative
They can differentiate into muscle, bone, cartilage, and fat cells.
Immunomodulatory
They regulate the immune system and can reduce inflammation.
Exosome Production
Through extracellular vesicles, they carry growth factors, proteins, and genetic material, forming the basis of their therapeutic properties.

Our Products
GMP-certified cell therapy products derived from Wharton's Jelly, offering cell-free therapeutic approaches with advantages of safety, efficacy, and ease of application.

MSC-V
Wharton's Jelly MSC
High-quality mesenchymal stem cells derived from umbilical cord Wharton's Jelly. Used in regenerative medicine for tissue repair, anti-aging treatments, and various therapeutic applications.

EXO-V
Wharton's Jelly MSC-derived Exosome
Exosomes derived from MSCs provide a cell-free therapeutic approach, carrying growth factors, proteins, and genetic material for targeted regenerative treatments.
Clinical Applications
MSC therapy has shown effectiveness across a wide range of conditions, with several treatments already approved in various markets worldwide.
| Condition | Clinical Phase | Market Approval |
|---|---|---|
| GVHD | Phase III | Yes (US & global) |
| Crohn's Disease | Phase III | Yes (EU & S. Korea) |
| Osteoarthritis | Phase III | Yes (S. Korea & Iran) |
| ALS | Phase II | Yes (S. Korea) |
| Spinal Cord Injury | Phase II | Yes (Japan) |
| Rheumatoid Arthritis | Phase II | In trials |

GMP-Certified Manufacturing
Located at Cube Incubation within Istanbul Teknopark, our state-of-the-art GMP facility enables the production of advanced cell and gene therapies meeting the highest international standards.
Vivosel has extensive regulatory and clinical experience in Türkiye, USA, and Europe.
Our Journey
Founded at Boğaziçi University
Established roots at the Center for Targeted Therapy Technologies at Boğaziçi University Kandilli Campus, bringing together leading scientists and biotechnology experts.
GMP Facility at Istanbul Teknopark
Opened a state-of-the-art GMP manufacturing facility to accelerate production of advanced cell and gene therapies.
MSC/Exosome Program Launch
Initiated a clinical program for innovative MSC/Exosome-based therapeutic approaches offering hope to patients with limited treatment options.
Board of Directors

Metin Kurtoğlu, M.D., Ph.D.
Co-founder
A third-generation physician with extensive medical experience, Metin completed his internal medicine training at Jackson Memorial Health/University of Miami and pursued medical oncology at the National Institute of Health. In 2016, he became Employee #1 at Cartesian Therapeutics, where he led the development of 5 ATMP products, including the world's first RNA-transfected CAR-T cell therapy for autoimmune disorders.

Utku Ateş, M.D., Ph.D.
Co-founder
With over 25 years of academic and industry experience in stem cells, tissue engineering, and cellular therapies, Utku founded the Ege University Cord Blood Bank—pioneering stem cell banking in Türkiye. He has served as Türkiye's Tissue & Cells Representative at Council of Europe EDQM meetings for over 17 years, shaping international standards.
Selected Publications
Ann Clin Transl Neurol • 2025
Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis
DOI: 10.1002/acn3.70167
Lancet Neurol • 2023
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis
DOI: 10.1016/S1474-4422(23)00194-1
Leukemia • 2021
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
DOI: 10.1038/s41375-020-0951-5
Our Capabilities
GMP Mesenchymal Stem Cells & Exosomes
MSC platforms and engineered exosomes for regenerative medicine, hair loss, and anti-aging treatments.
GMP Gene Editing Platforms
End-to-end GMP process development for gene editing applications.
GMP-Grade Cell Products
High-quality cell lines and raw materials for clinical research.
Quality Control Laboratory
In-house QC for EMA and FDA-aligned standards.
Learn More About Vivosel
Visit the Vivosel website to explore our research, publications, and ongoing clinical collaborations.
Visit Website